Serological indication of chronic inflammatory demyelinating polyneuropathy as an extrahepatic manifestation of hepatitis E virus infection
Guillain-Barré syndrome and neuralgic amyotrophy have been associated with hepatitis E virus (HEV) genotype 3 infections, while myasthenia gravis (MG) has been associated with HEV genotype 4 infections. However, whether chronic inflammatory demyelinating polyneuropathy (CIDP) is associated with HEV infections has not been conclusively clarified yet. 102 CIDP patients, 102 age- and sex-matched blood donors, 61 peripheral neuropathy patients (non-CIDP patients), and 26 MG patients were tested for HEV and anti-HEV IgM and IgG. Sixty-five of the 102 (64%) CIDP patients tested positive for anti-HEV IgG and one (1%) for anti-HEV IgM. No other patient tested positive for ati-HEV IgM. In the subgroup of CIDP patients with initial diagnosis (without previous IVIG treatment), 30/54 (56%) tested positive for anti-HEV IgG. Anti-HEV rates were significantly lower in blood donors (28%), non-CIDP peripheral neuropathy patients (20%), and MG patients (12%). No subject tested positive for HEV viremia. CSF tested negative for in 61 CIDP patients (54 patients with primary diagnosis). The development of CIDP but not non-CIDP polyneuropathy may be triggered by HEV exposure in an HEV genotype 3 endemic region. The increased anti-HEV seroprevalence in CIDP patients is not a consequence of IVIG therapy.
Authors
- Johannes H. Bannasch
- Thomas Skripuletz (ORCID: https://orcid.org/0000-0001-8550-335X)
- Tabea Seeliger (ORCID: https://orcid.org/0000-0002-6018-6826)
- Stefan Gingele (ORCID: https://orcid.org/0000-0002-6055-5695)
- Thomas Horvatits (ORCID: https://orcid.org/0000-0003-0682-4476)
- Jens Hiller (ORCID: https://orcid.org/0000-0002-4273-8586)
- Julian Schulze zur Wiesch (ORCID: https://orcid.org/0000-0002-5033-1938)
- Mathias Gelderblom (ORCID: https://orcid.org/0000-0002-4254-3439)
- Franz Felix Konen (ORCID: https://orcid.org/0000-0002-8609-5674)
- Amir Golsari
- Sven Pischke (ORCID: https://orcid.org/0000-0003-3370-3274)
- M. Mader
- Christian Casar (ORCID: https://orcid.org/0000-0002-8624-1045)
- Samuel Huber (ORCID: https://orcid.org/0000-0001-9325-8227)
- Sven Peine (ORCID: https://orcid.org/0000-0002-6365-9916)
- Andrzej Wolski (ORCID: https://orcid.org/0000-0002-2968-0949)
- A. Kjasimov
- G. Thayssen
- Marc Lütgehetmann (ORCID: https://orcid.org/0000-0002-9468-7944)
Institutions
- Universität Hamburg (DE)
- Medizinische Hochschule Hannover (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- German Center for Infection Research (DE)
Publication Details
- Journal
- Scientific Reports
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1038/s41598-024-70104-3
- Citations
- 1
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.37
Funders
- Bristol-Myers Squibb Foundation
- Bristol-Myers Squibb
- Pfizer
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Celgene
- CSL Behring
- Deutsches Zentrum für Infektionsforschung
- Argenx
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Else Kröner-Fresenius-Stiftung
- Swedish Orphan Biovitrum
- Sanofi Genzyme
- Bayer Vital